Multiplexing is crucial for analyzing multiple analytes in a single assay volume. As the same assay volume can analyze ten different analytes, multiplexing saves the amount of sample required for analysis and also reduces the number of assay plates. Thus multiplexing capacities are crucial when assessing drug action, toxicity, or discovering novel biomarkers. Drug discovery involves evaluating thousands of molecules to identify a potential drug compound. Hence, multiplexing is invaluable for the drug discovery process.
Meso Scale Discovery multiplex assays are a robust platform for analyzing multiple analytes in biological matrices. It combines electrochemiluminescence with Multi-array technology to bring high-speed and ultra-dense information through miniaturization and parallel processing. Besides, the meso scale discovery assay
are available in a wide range of assay kits suited for every stage of the drug discovery process. Let us dive deep and understand high-throughput multiplex antibody-based detection with MSD Meso Scale assays.
Meso Scale Discovery multiplex assays for antibody-based detection
Today, MSD assays are adopted widely by pharmaceutical companies, drug developers, the biotech industry, and research organizations. If researchers want to assess multiple analytes in smaller volumes, MSD is their go-to multiplexing technique. Currently providing over 400 different assays and customization options, MSD can help researchers accurately quantify different phosphoproteins, cytokines, and biomarkers levels in different study matrices. Besides, high-quality data can be obtained in a shorter time with lesser effort and minimal costs. Meso Scale Discovery has two types of multiplexing assays; V-Plex and U-Plex assays.
V-Plex assays are validated assays that researchers can use without any prior preparation. Though MSD provides pre-validated panels, researchers can customize them by selecting analytes from a wide range of validated panels. MSD then prepares these custom plates and validates them for the user.
U-Plex is a customizable alternative. However, U-Plex assays are not validated and require preparation by the user. A significant difference between U-Plex and V-Plex assay is that U-Plex needs researchers to conduct biotin-streptavidin reactions for binding the proteins. However, this manual step allows the freedom of choosing antibody combinations that are not feasible with V-Plex assays. Let us dive deeper into each of these assay types.
V-Plex means validated assays. All V-Plex assays are thoroughly validated, and MSD provides a certificate of analysis to the user. Moreover, the validation includes:
- The lower limit and upper limit of quantification
- Percent recovery and %CV
- Amount of nonspecific binding
- Standard curve data
- And full GMP and GLP validations.
U-Plex means assays for you. Thus, these assays are designed particularly for the customer. MSD provides any combination of target analytes to be used in the U-Plex system. Moreover, MSD has a specialized biotin-streptavidin system developed to ease the selection process. Currently, MSD has over 75 biotin-labeled antibodies for U-Plex assays. Researchers can then link the biotin-labeled antibody to a specialized “U-Plex Linker” through the biotin-streptavidin binding system. Later these systems can be placed at respective locations within the MSD plates.
Thus, V-Plex and U-Plex are robust MSD platform alternatives for high throughput multiplex antibody detection.